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least important outcomes for antithrombotic therapy. These results might be 
informative for making treatment decisions.  
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QUALITY OF LIFE AFTER EPIC NITINOL STENT PLACEMENT: 12-MONTH 
OUTCOMES FROM THE ORION STUDY  
Hale BC1, Drawert S1, Gu X1, Diaz-Cartelle J1, Clair D2 
1Boston Scientific, Natick, MA, USA, 2Cleveland Clinic Foundation, Cleveland, OH, USA  
OBJECTIVES: Symptoms of peripheral arterial disease (PAD) are frequently 
associated with impaired health-related quality-of-life (HRQOL), which, in turn, 
impacts overall life satisfaction. However, there are few reports of patient 
expectations related to PAD interventions. The purpose of this analysis was to 
evaluate treatment-related changes in HRQOL in the ORION study. METHODS: 
ORION enrolled 125 patients, at 28 US centers, who had been diagnosed with 
chronic, symptomatic iliac disease. Patients received ≤2 nitinol stents in the 
common and/or external iliac artery. The Walking Impairment Questionnaire 
(WIQ), a validated PAD-specific quality-of-life instrument, was completed by 
each patient to assess his or her walking distance, walking speed, and stair-
climbing ability. RESULTS: Significant improvements (p<.0001) in all 3 domain 
scores of the WIQ were reported at 12 months postintervention. The walking 
distance mean score increased from 14.56±19.36 at baseline to 55.88±38.02 at 12 
months. Walking speed and stair-climbing mean scores increased from 
18.38±19.18 and 26.14±26.91, respectively, at baseline to 47.96±31.80 and 
57.72±37.17 at 12 months. Prior to intervention, 20.2% of patients were able to 
walk no more than 50 feet and 21.0% could walk at least 1500 feet. Improvement 
in maximum walking distance was observed; at 12 months, only 5.5% of patients 
could walk no more than 50 feet, while 63.3% could walk at least 1500 feet. 
Postintervention, there was an approximately 5-fold increase in patients who 
could run/jog one city block at 12 months (34.9%), compared to baseline (7.3%) 
and an approximately 2-fold increase in those who could climb at least 3 flights 
of stairs at 12 months (62.4%), compared to baseline (32.3%). CONCLUSIONS: 
Significant improvements in HRQOL, related to walking and stair climbing 
ability, were observed after nitinol stent placement. Future studies will target 
whether pretreatment HRQOL patient education affects patient perception and 
satisfaction related to the procedure and provider.  
 
PCV117  
STRUCTURED REVIEW OF PATIENT-REPORTED OUTCOME INSTRUMENTS FOR 
ASSESSING PATIENTS WITH ATRIAL FIBRILLATION  
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OBJECTIVES: To evaluate the characteristics of existing patient-reported 
outcome (PRO) instruments assessing atrial fibrillation (AF)-specific health-
related quality of life (HRQOL) or symptoms, focusing on Food and Drug 
Administration (FDA) PRO guidance. METHODS: This review was conducted in 
two phases. In phase 1, multiple sources (PubMed, Embase, Patient-Reported 
Outcome and Quality of Life Instruments Database [PROQOLID], and 
ClinicalTrials.org) were reviewed to identify instruments. In phase 2, data related 
to the development and measurement properties (internal consistency and test-
retest reliability, convergent and divergent construct validity, known-groups 
validity, and responsiveness) of these instruments were compared. RESULTS: 
The literature search identified 625 studies. Six AF-specific measures were 
identified: four HRQOL instruments (Atrial Fibrillation Effect on Quality-of-Life 
[AFEQT], Atrial Fibrillation Quality of Life [AF-QoL], AF6 [a six-item AF 
questionnaire], Questionnaire for Quality of Life in AF [QLAF]) and two symptom 
assessments (Symptom Checklist—Frequency and Severity [SCL], University of 
Toronto Atrial Fibrillation Severity Scale [AFSS]). The AFEQT extensively involved 
AF patients in its development, establishing content validity. The AFEQT 
demonstrated robust measurement properties including internal consistency 
Cronbach’s alphas of 0.88-0.95 for domains, test-retest intraclass correlation 
coefficients of 0.7-0.8 for three of four domains and overall score, evidence of 
construct and known-groups validity, and responsiveness to treatment-related 
changes in a longitudinal study. The SCL and AFSS have demonstrated 
responsiveness in randomized controlled trial (RCT) settings but neither involved 
AF patients in the development process, and both have limited published 
psychometric validation data. CONCLUSIONS: No existing PRO measure appears 
likely to support an FDA PRO label claim in AF. The AFEQT is the strongest 
instrument for measuring AF-related HRQOL; additional studies are needed to 
assess responsiveness in RCT settings. The SCL and AFSS have significant 
limitations related to development and validation. Qualitative research with AF 
patients may provide support for the content validity of the symptom measures.  
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OBJECTIVES: The health related quality of life (HRQoL) among hypertensive 
patients is influenced by a number of factors. However, there is paucity of 
information on the determinants of HRQoL among hypertensive patients 
particularly from developing countries such as Pakistan. This study therefore 
aims to describe the predictors and correlates of HRQoL in a hypertensive 
population of Pakistan. METHODS: A questionnaire based, cross sectional study 
was conducted among 385 hypertensive patients visiting two public hospitals in 
the city of Quetta, Pakistan. Demographic and disease related data was obtained 
from the patients and their hospital records. The generic EQ-5D questionnaire 
was used to measure HRQoL while Drug Attitude Inventory and Hypertension 
Fact Questionnaire were used to measure medication adherence and 
hypertension related knowledge respectively. Scale scores were compared with 
Mann-Whitney and Kruskal-Wallis test. Spearman's rho correlation was used to 
envisage the correlates of HRQoL. Standard multiple regression analysis was 
performed to identify predictors of HRQoL. RESULTS: Patients in the current 
study reported poor HRQoL with mean score of 0.46±0.28. In terms of practical 
implementation, age (β=0.298, p<0.001), educational level (β=0.493, p=0.025) and 
knowledge score (β=0.351, p=0.024) reached level of significance in the 
multivariate analysis. The multiple regression analysis also found that variables 
like gender, occupation, income, locality, duration of disease and medication 
adherence were not significantly associated with HRQoL. CONCLUSIONS: The 
results of the present study provide an evidence for a model that correlates with 
patients’ socio-demographic information and HRQoL. The findings after 
implication in clinical practice can prove useful in guiding patients receiving 
treatment for HTN. It will also help the physicians to maintain and adjust 
treatment behaviours with drug or non drug related interventions.  
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OBJECTIVES: Although hypercholesterolemia (high levels of cholesterol in the 
blood) itself is asymptomatic, longstanding elevation of serum cholesterol can 
lead to increase the risk of cardiovascular disease, particularly coronary heart 
disease. In Russia, there are no solid estimates of the magnitude of this 
condition. This study is aimed to assess co-morbidity, quality of life (QoL), work 
productivity loss, activity impairment, and medical resource utilization in 
Russian urban adults with hypercholesterolemia. METHODS: Patients’ self-
reported data were collected from 2011 National Health and Wellness Survey 
(NHWS). Survey sample represented major urban areas in Russia. QoL was 
measured by the physical component summary (PCS) and mental component 
summary (MCS) scores of the SF-12v2 . Work productivity loss and activity 
impairment were measured by the validated Work Productivity and Activity 
Impairment (WPAI) questionnaire. Medical resource utilization was measured by 
health care provider visits, emergency room visits, and hospitalizations in the 
past 6 months. RESULTS: Of the 10,039 adult respondents, 802 (7.98%) were 
experiencing hypercholesterolemia, of which 89% self-reported physician 
diagnosis, and only 60% were currently using some sort of medication. Average 
age of patients diagnosed with high cholesterol was 53.2 years. Compared to 
those not experiencing hypercholesterolemia, the diagnosed group reported 
more comorbidities (headache 66%, hypertension 54%, sleep difficulties 54%, 
insomnia 44%, pain 41%, heartburn 40%), lower mean PCS (40.7 vs. 47.1), and 
similar MCS (41.8 vs. 43.8). More patients visited health care providers (88% vs. 
70%) and a higher percentage were hospitalized (14% vs. 9%) over the past 6 
months. Furthermore, hypercholesterolemia patients reported 34.2% impairment 
in daily activities compared to 25.0% in the not experiencing 
hypercholesterolemia group. All mentioned differences were statistically 
significant (p<0.05). CONCLUSIONS: From Russian NHWS results, patients 
experiencing hypercholesterolemia suffer from lower QOL, work productivity 
loss, and more comorbidities. Findings indicate there is still an unmet medical 
need in Russian hypercholesterolemia patients.  
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OBJECTIVES: To evaluate demographic, diagnostic, and treatment characteristics 
of patients with concomitant hypertension and dyslipidemia, stratified by body 
mass index (BMI) and the attainment of blood pressure (BP) and lipid targets in 
obese versus non-obese patients. METHODS: This retrospective study utilized 
data from 2004 to 2011 from the GE Centricity Electronic Medical Records 
database of a primary care physician group in Southwestern Pennsylvania. 
Patients having ‘active’ status (with one or more visit(s) to the physician), ≥18 
years of age, and having concomitant hypertension and dyslipidemia (identified 
based on diagnosis, medication, and BP/lipid measurements) were included. 
Patients were classified into three cohorts based on their BMI: normal-weight 
(≤24.9 kg/m2), overweight (25.0-29.9 kg/m2), and obese (≥30.0 kg/m2). Goal 
attainment for BP and lipid levels were assessed based on JNC 7 and NCEP ATP III 
guidelines, respectively. Univariate and multivariate analyses were conducted to 
compare BP and lipid goal attainment in obese versus non-obese. RESULTS: A 
total of 9,086 patients with concomitant hypertension and dyslipidemia were 
identified and categorized as normal weight (13.8%), overweight (33.7%) and 
obese (52.5%). Patients who were obese were younger (<65 years); more likely to 
have diabetes (P<0.001); had higher baseline BP, triglyceride levels and lower 
HDL-C (P<0.05); and more likely to be prescribed both antihypertensives and 
antilipemic agents (P<0.001). In multivariate analyses, obese patients were 
significantly more likely to fail to attain BP (OR=1.562, P<0.001) and dual BP and 
LDL-C (OR=1.193, P=0.023) goals as well as optimal levels of triglycerides 
(OR=1.864, P<0.001) and HDL-C (OR=1.933, P=0.009). CONCLUSIONS: Obesity 
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appears to be an independent risk factor for the failure to attain BP and dual BP 
and LDL-C goals in patients with concomitant hypertension and dyslipidemia. 
These findings suggest that future research is needed to determine the 
underlying link between obesity and failure to attain these goals.  
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UTILIZATION OF POLYPILL FOR MANAGEMENT OF MYOCARDIAL  
INFARCTION  
Gupta P, Aparasu RR 
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BACKGROUND: Past literature recommends varied combinations of 2 or more 
anti-hypertensive drugs as polypill therapy for Myocardial Infarction (MI). 
OBJECTIVES: This study examined the utilization pattern and predictors of the 
most combinations for MI patients. METHODS: Data from 2009 Medical 
Expenditure Panel Survey (MEPS) was employed to examine the use of anti-
hypertensive drug combinations among MI patients, defined by ICD-9-CM code 
‘410’. Using MEPS sampling weights, descriptive analysis and survey logistic were 
used to evaluate prevalence and predictors of utilizing 2 or more anti-
hypertensive drug combinations among MI patients. RESULTS: An estimated 
5.91million patients (1.93%, 95%CI: 1.70%-2.15%) were diagnosed with MI in 2009. 
Of these, 5.03 million patients (85.92%, 95%CI: 82.62%-89.22%) were using at least 
one anti-hypertensive and 3.60million patients (60.87%, 95%CI: 56.19%-65.55%) 
were using a combination of ≥2 anti-hypertensives. Most frequently utilized 
combination of ≥2 anti-hypertensives was of Angiotensin inhibitors or 
Angiotensin receptor blockers (ACEARB) and Beta-blockers (BBS) with a 
prevalence of 2.41million patients (40.86%, 95%CI: 36.35%-45.36%). Multivariate 
analysis revealed Hypertension (OR 2.43: 1.49 – 3.96), Congestive Heart Failure or 
CHF (OR 3.05: 1.33 – 7.00), and Chronic Atherosclerosis (OR 2.08: 1.32 – 3.29) as its 
statistically significant predictors of two or more hypertensive combinations. 
The most prevalent combination of ≥3 anti-hypertensives was for a combination 
of ACEARB, BBs and Diuretics with a prevalence of 1.19 million (20.11%, 95%CI: 
16.52%-23.70%). The significant predictors of utilizing this combination were 
Presence of any limitation (OR 3.47: 1.69 – 7.13), Hypertension (OR 2.22: 1.08 – 
4.58), CHF (OR 6.10: 2.92 – 12.73), and Chronic Atherosclerosis (OR 2.03: 1.12 – 
3.70). CONCLUSIONS: Combinations of ACEARB and BBs with or without 
Diuretics were the most commonly used combinations in patients with MI. 
Comorbid hypertension, CHF and Chronic atherosclerosis were the primary 
disease-based predictors of these combinations.  
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OBJECTIVES: Customer segmentation is a strategic tool employed by the 
pharmaceutical and life sciences industries traditionally focusing on 
understanding physicians and patients. With resources and budget cuts, 
pharmaceutical companies have increasingly identified the need to successfully 
and cost-effectively prioritise and target payers by understanding their drivers, 
motivations, barriers and limitations when assessing, endorsing or restricting 
new products. Our study aimed to develop an attitudinal based, scalable payer 
segmentation model to investigate payers’ attitudes and behaviours towards the 
managed entry of novel agents in the cardiology area in the health care systems 
of countries within the EU. METHODS: A quantitative data collection and 
advanced statistical analysis methodology was employed with regional and local 
payers in eight markets to define the segmentation according to attitudes and 
beliefs relevant to the therapy area. Subsequently, in-depth semi-structured 
telephone interviews were conducted to explore the rationale behind payers’ 
views, along with perceived challenges relating to the entry of novel class of 
cardiovascular agents. RESULTS: Quantitative segmentation identified four key 
distinct segments of payers displaying unique attitudes and beliefs towards 
entry of the novel class of cardiovascular agents. The segmentation approach 
identified key differentiating factors between segments, allowing full profiling of 
each group. Payers’ underlying values were identified and expanded upon 
resulting in insight to what is important to them as individuals as well as 
decision-makers, what motivates them and what restricts them. CONCLUSIONS: 
This method of segmentation proved valuable in gaining payer insights which 
were utilized to prioritise targeting of payer segments. In addition, 
communication and messaging strategies were optimised for these payer groups. 
The findings helped inform service redesign strategies within health care 
systems to include the novel agents in the treatment guidelines and to reduce 
human and financial resources when treating the specific condition.  
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OBJECTIVES: The prompt treatment of ST segment elevation myocardial 
infarction (STEMI) is associated with conservation of cardiac function and 
reduced mortality. Acquisition of pre-hospital electrocardiogram (ECG) by first 
responders and digital transmission of the ECG to the hospital has been 
identified as a strategy to reduce time to treatment to the recommended 90 
minutes. The purpose of this study was to summarize the literature on the 
difference between patients with pre-hospital ECG to patients with in-hospital 
ECG. METHODS: This systematic review of MEDLINE indexed articles used the 
terms Dyspnea [MeSH] OR Chest Pain [MeSH] OR Myocardial Infarction/therapy 
[MAJR] with Time Factor [MeSH] and Comparative Study [pub type]. Study 
inclusions were: English, human, publication between January 1, 2002 to 
November 30, 2012. Case reports, letters, news articles and reviews were 
excluded. Comparative studies which included a group with pre-hospital ECG 
with transmission to the hospital and a control group of patients with in-
hospital ECG were eligible for inclusion. The data outcomes extracted included 
patient characteristics, onset to treatment (OTT) and door to treatment time 
(DTT). RESULTS: The search found 1029 articles, 8 passed two-tiered screening 
and were extracted. Three studies described thrombolysis, six studies described 
angioplasty (one study included both treatments). Four studies reported OTT, the 
pre-hospital ECG group had statistically significant shorter times (range 64-260 
min pre-hospital ECG and 103-432 min in-hospital ECG). Six studies reported DTT 
the pre-hospital ECG group were statistically significantly shorter (range 20-100 
min pre-hospital ECG group and 17-133 in-hospital ECG). Pre-hospital groups 
reported median DTT of <90 minutes (range 50-66 min). CONCLUSIONS: This 
review found significant beneficial differences in the onset to treatment and 
door to treatment times of STEMI patients with pre-hospital ECG. Transmission 
of pre-hospital ECG is an important component of a strategy to achieve door to 
treatment times of under 90 minutes.  
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OBJECTIVES: To determine the cost-effectiveness of Transcatheter aortic valve 
implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in a 
high-risk aortic stenosis (AS) population from the perspective of the UK health 
and personal social services. METHODS: A Markov model was developed to 
enable a cost-utility analysis employing NICE reference case methods. A 
systematic review was conducted to identify model parameter values. Mean 
utility values per NYHA category were derived from a UK high-risk AS 
population. Two-year TAVI and SAVR effectiveness was taken from the PARTNER 
A trial. Costs and effects were modelled from two years over a 10 year horizon 
via NYHA health state transitions. Incremental cost-effectiveness ratios (ICER) 
and cost effectiveness acceptability curves (CEAC) were calculated and 
deterministic and probabilistic sensitivity analyses conducted. RESULTS: Despite 
greater procedural costs (£16,500 vs. £9,256), TAVI was cost-effective compared to 
SAVR over 10 years (costs £52,593 vs. £53,943 and QALYs 2.81 vs 2.75), indicating 
TAVI dominated SAVR. This appeared to be due to greater SAVR post-surgical 
costs and attendant length and cost of hospital stay. The results appeared robust 
to a number of deterministic sensitivity (including high stroke rates, worst case 
scenario complication rates, alternative utility values and higher costs) and 
probabilistic analyses. Given modest cost savings and QALY benefits conferred 
by TAVI, results were sensitive to some parameter changes when incurred by 
one arm in isolation. The CEAC indicated that at a £20,000 incremental QALY 
willingness to pay threshold, TAVI had a 64.6% likelihood of being cost-effective. 
CONCLUSIONS: This economic evaluation is the first to incorporate two year 
data comparing TAVI and SAVR in elderly high risk AS patients. TAVI is likely to 
be a cost-effective option compared to SAVR. However, uncertainty surrounding 
the long-term outcomes for TAVI patients remains; this could have a substantive 
impact on estimates of cost-effectiveness.  
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OBJECTIVES: Cigarette smoking is a major risk factor for cardiovascular disease. 
Recent research has shown that deaths due to cardiovascular problems are 
double in women who smoke. The use of smoking cessation agents is one of the 
most effective ways to quit smoking. The purpose of this study is to analyze 
trends in smoking status and utilization of smoking cessation agents in women 
with cardiovascular disease from 2001-2010. METHODS: A longitudinal 
retrospective database analysis was done to identify smokers with 
cardiovascular disease during the period from 2001 to 2010 by using Medical 
Expenditure Panel Survey (MEPS) data. Trends in smoking status and patient 
reported use of smoking cessation agents were observed to compare prevalence 
of smoking and use of cessation agents among women. RESULTS: A cohort of 
8331 smokers with cardiovascular disease was identified over a 10 year period 
which showed more female smokers than males. There was an inconsistent 
increase in the number of female smokers from 2001 to 2010 with maximum 
smokers of 54.33% in 2003. After 2003, the percentage of female smokers started 
decreasing inconsistently. Female smokers using smoking cessation agents in 
2007 were 8.51% and later there was a consistent decrease in the use of these 
agents until 2010, which reached 5.29%. The 10-year data showed that females 
were more likely to use smoking cessation agents than males. CONCLUSIONS: 
Despite the increased risk among female smokers, results indicate higher 
prevalence of smoking among women. Although the utilization of smoking 
cessation is increasing, overall proportion of users is still considerably low. There 
is a need for continued efforts to reduce smoking among women more 
aggressively. Increasing utilization of smoking cessation agents may help in 
changing current trends.  
